Login to Your Account

Alkermes launches phase I in MS with eye on Biogen's Tecfidera

By Michael Fitzhugh
Staff Writer

Friday, July 18, 2014
Alkermes plc is ramping up a phase I study of ALKS-8700, a small-molecule prodrug of monomethyl fumarate (MMF) for the treatment of multiple sclerosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription